Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/8/12 → 3/8/16 |
Funding
- Parexel (VX11-950-114 // VX11-950-114)
- Vertex Pharmaceuticals Incorporated (VX11-950-114 // VX11-950-114)
Prot # VX11-950-114: A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype
- Flamm, Steven L (PD/PI)
- Ganger, Daniel R (Co-PD/PI)
Project: Research project